Skip to main content
HCPCS J9041 · Level II · Part B drug

J9041: bortezomib (Velcade), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J9041

Billing unit
0.1 MG
Injection, bortezomib, 0.1mg
ASP payment limit
$2.628
October 2026; +29.0% vs July 2026
Practitioner MUE
35
MAI 3
OPPS status
SI N
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J9041 is the Level II code for Injection, bortezomib, 0.1 mg, billed per 0.1 MG. The Medicare Part B ASP payment limit for October 2026 is $2.628 per billing unit, up 29.0% from July 2026. The practitioner MUE allows up to 35 units per date of service (MAI 3), so a full 35-unit day is $91.98 at the current limit. Under OPPS it carries status indicator N. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. Other HCPCS codes whose descriptor names bortezomib: J9049 (the Hospira product (manufacturer named in its CMS descriptor); not therapeutically equivalent to J9041); J9054 (Boruzu from Amneal Pharmaceuticals, LLC); J9046 (the Dr. Reddy's product (manufacturer named in its CMS descriptor); not therapeutically equivalent to J9041; billed per 0.1 mg); J9048 (the Fresenius Kabi product (manufacturer named in its CMS descriptor); not therapeutically equivalent to J9041; billed per 0.1 mg). The ASP crosswalk maps 20 NDCs to it, sold as Bortezomib, Velcade by Hikma Pharmaceuticals USA Inc., Pfizer Inc, Baxter Healthcare Corporation. No current Billing and Coding Article lists J9041, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J9041 at $2.628 per 0.1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $2.037 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J9041
QuarterPayment limitPerCoinsurance
October 2026$2.6280.1 MG20%
July 2026$2.0370.1 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 20 NDCs from 17 labelers to J9041. Report the NDC in the claim's drug segment and bill the number of J9041 units that equals the quantity administered divided by 0.1 MG; the last column gives units per full package.

NDCs that crosswalk to J9041
NDCDrug nameLabelerPackage sizeBilling units / package
00143-9098-01BortezomibHikma Pharmaceuticals USA Inc.1 × 135
00409-1700-01BortezomibPfizer Inc1 × 135
10019-0991-01BortezomibBaxter Healthcare Corporation1 × 135
25021-0244-10BortezomibSagent Pharmaceuticals1 × 135
25021-0262-10BortezomibSagent Pharmaceuticals1 × 135
43598-0426-60BortezomibDr. Reddy's Laboratories Inc.1 × 135
50742-0484-01BortezomibIngenus Pharmaceuticals LLC1 × 135
55150-0337-01BortezomibEugia US LLC1 × 135
60505-6050-04BortezomibApotex Corp1 × 135
63020-0049-01VelcadeTakeda Pharmaceuticals America, Inc.1 × 135
63323-0821-10BortezomibFreseniUS Kabi USA, LLC1 × 135
68001-0534-36BortezomibBluePoint Laboratories1 × 135
68001-0540-36BortezomibBluePoint Laboratories1 × 135
68001-0541-36BortezomibBluePoint Laboratories1 × 135
70069-0836-01BortezomibSomerset Pharma, LLC1 × 135
70710-1411-01BortezomibZydus Pharmaceuticals (USA) Inc.1 × 135
70860-0225-10BortezomibAthenex Pharmaceutical Division, LLC1 × 135
71288-0118-10BortezomibMeitheal Pharmaceuticals Inc.1 × 135
72205-0183-01BortezomibNovadoz Pharmaceuticals LLC1 × 135
72603-0270-01BortezomibNorthstar RxLLC1 × 135

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J9041. For practitioners the limit is 35 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J9041 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services353 Date of Service Edit: ClinicalClinical: Data
Facility outpatient hospital353 Date of Service Edit: ClinicalClinical: Data
DME supplier353 Date of Service Edit: ClinicalPrescribing Information

MUE for J9041 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J9041 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J9041 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J9041 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J9041 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J9041 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J9041 carries payment indicator N1, which CMS defines as "Packaged service/item; no separate payment made". An N1 drug is packaged in the ASC: the facility receives no separate payment because the surgical procedure's rate already includes it.

Common denials for J9041 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J9041

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J9041

What does HCPCS code J9041 describe?

J9041 is defined by CMS as "Injection, bortezomib, 0.1 mg". Each billing unit represents 0.1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J9041 a CPT code?

No. J9041 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as bortezomib (Velcade); CPT codes are five-character codes maintained by the AMA. On a Part B claim J9041 reports the drug itself in 0.1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J9041 in October 2026?

The ASP-based payment limit is $2.628 per 0.1 MG, with 20% beneficiary coinsurance. The July 2026 limit was $2.037. Commercial payers use their own fee schedules.

How many units of J9041 can be billed per day?

The practitioner Medically Unlikely Edit is 35 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Clinical: Data" as the rationale.

Which NDCs map to J9041?

The October 2026 ASP crosswalk lists 20 NDCs from 17 labelers: Bortezomib (Hikma Pharmaceuticals USA Inc.); Bortezomib (Pfizer Inc); Bortezomib (Baxter Healthcare Corporation); Bortezomib (Sagent Pharmaceuticals). For example NDC 00143-9098-01 (package size 1) equals 35 billing units of J9041.

Does J9041 have NCCI bundling edits?

No active practitioner PTP pairs list J9041 as a column-1 or column-2 code in the v323r0 release.

J9041 vs J9049: what is the difference?

Both are HCPCS Level II codes whose descriptor names bortezomib. What sets J9049 apart: the Hospira product (manufacturer named in its CMS descriptor); not therapeutically equivalent to J9041. J9041 is billed per 0.1 mg, limit $2.628, MUE 35; J9049 is billed per 0.1 mg, limit $1.531, MUE 35. Report the code whose descriptor matches the product and setting in the record.

J9041 vs J9054: what is the difference?

Both are HCPCS Level II codes whose descriptor names bortezomib. What sets J9054 apart: Boruzu from Amneal Pharmaceuticals, LLC. J9041 is billed per 0.1 mg, limit $2.628, MUE 35; J9054 is billed per 0.1 mg, limit $23.905, MUE 70. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.